Glucocorticoid-based pharmacotherapies preventing PTSD
Por:
Florido, A, Velasco, ER, Monari, S, Cano, M, Cardoner, N, Sandi, C, Andero, R, Perez-Caballero, L
Publicada:
15 feb 2023
Ahead of Print:
17 nov 2022
Resumen:
Posttraumatic stress disorder (PTSD) is a highly disabling psychiatric condition that may arise after exposure to acute and severe trauma. It is a highly prevalent mental disorder worldwide, and the current treatment options for these patients remain limited due to low effectiveness. The time window right after traumatic events provides clinicians with a unique opportunity for preventive interventions against potential deleterious alterations in brain function that lead to PTSD. Some studies pointed out that PTSD patients present an abnormal function of the hypothalamic-pituitary-adrenal axis that may contribute to a vulnerability toward PTSD. Moreover, glucocorticoids have arisen as a promising option for preventing the disorder's development when administered in the aftermath of trauma. The present work compiles the recent findings of glucocorticoid administration for the prevention of a PTSD phenotype, from human studies to animal models of PTSD. Overall, glucocorticoid-based therapies for preventing PTSD demonstrated moderate evidence in terms of efficacy in both clinical and preclinical studies. Although clinical studies point out that glucocorticoids may not be effective for all patients' subpopulations, those with adequate traits might greatly benefit from them. Preclinical studies provide precise insight into the mechanisms mediating this preventive effect, showing glucocorticoid-based prevention to reduce long-lasting behavioral and neurobiological abnormalities caused by traumatic stress. However, further research is needed to delineate the precise mechanisms and the extent to which these interventions can translate into lower PTSD rates and morbidity.
Filiaciones:
Florido, A:
Univ Autonoma Barcelona, Inst Neurociencies, Barcelona, Spain
Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Barcelona, Spain
Velasco, ER:
Univ Autonoma Barcelona, Inst Neurociencies, Barcelona, Spain
Monari, S:
Ecole Polytech Fed Lausanne, Sch Life Sci, Brain Mind Inst, Lab Behav Genet, Lausanne, Switzerland
Geneva Univ Hosp HUG, Dept Psychiat, CH-1225 Geneva, Switzerland
Cano, M:
Hosp Santa Creu & Sant Pau, Inst Invest Biomed St Pau IIB St Pau, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain
Cardoner, N:
Hosp Santa Creu & Sant Pau, Inst Invest Biomed St Pau IIB St Pau, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain
Univ Autonoma Barcelona, Sch Med Bellaterra, Dept Psychiat & Forens Med, Barcelona, Spain
Sandi, C:
Ecole Polytech Fed Lausanne, Sch Life Sci, Brain Mind Inst, Lab Behav Genet, Lausanne, Switzerland
Andero, R:
Univ Autonoma Barcelona, Inst Neurociencies, Barcelona, Spain
Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain
Univ Autonoma Barcelona, Inst Neurociencies, I3PT, Unitat Neurociencia Traslac, Parc Tauli Hosp Univ, Cerdanyola Del Valles, Spain
ICREA, Barcelona, Spain
Perez-Caballero, L:
Univ Autonoma Barcelona, Inst Neurociencies, Barcelona, Spain
Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Barcelona, Spain
hybrid, All Open Access; Hybrid Gold
|